Pharming Group NV (PHAR NASDAQ) stock market data APIs
$13.2309
-0.3(-2.3%)
as of November 4, 2025
Try our APIs with
free plan!
Pharming Group NV Financial Data Overview
Price chart is built with
Anychart
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Prev. Close
13.2309
Open
12.9279
High
13.2309
Low
12.9279
52 wk Range
7.31-17.08
Market Cap
902 M
Shares Outstanding
68 515 K
Revenue
340 M
Beta
0.186
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pharming Group NV data using free add-ons & libraries
Get Pharming Group NV Fundamental Data
Pharming Group NV Fundamental data includes:
- Net Revenue: 340 M
- EBITDA: 26 370 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-22
- EPS/Forecast: -0.125
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pharming Group NV News
New
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Hea...
European Penny Stocks To Consider In October 2025
The European markets have shown resilience with the pan-European STOXX Europe 600 Index climbing 1.68% and major stock indexes across the continent experiencing gains, reflecting a robust economic out...
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for ...
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentati...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
